Do analysts rate MOR or ESPR?

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Esperion Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend RGC or ESPR?

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Esperion Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, RGC or ESPR?

Regencell Bioscience has higher earnings, but lower revenue than Esperion Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Esperion Therapeutics $403.14M 2.03 -$22.68M -$0.06 N/A

Esperion Therapeutics (ESPR) Competitors

$3.18 0.00 (0.00%)

As of 07/13/2026

Compare

ESPR vs. ARQT, MOR, TARS, SUPN, and RGC

Should you buy Esperion Therapeutics stock or one of its competitors? Esperion Therapeutics's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MorphoSys (MOR), Tarsus Pharmaceuticals (TARS), Supernus Pharmaceuticals (SUPN), and Regencell Bioscience (RGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Esperion Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Esperion Therapeutics (NASDAQ:ESPR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

47.4% of Esperion Therapeutics shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Arcutis Biotherapeutics had 39 more articles in the media than Esperion Therapeutics. MarketBeat recorded 39 mentions for Arcutis Biotherapeutics and 0 mentions for Esperion Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.75 beat Esperion Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Positive
Esperion Therapeutics	Neutral

Arcutis Biotherapeutics has higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	7.09	-$16.14M	$0.21	124.71
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Arcutis Biotherapeutics currently has a consensus price target of $35.57, indicating a potential upside of 35.82%. Esperion Therapeutics has a consensus price target of $5.54, indicating a potential upside of 74.21%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arcutis Biotherapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Esperion Therapeutics' net margin of 0.12%. Arcutis Biotherapeutics' return on equity of 15.05% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Arcutis Biotherapeutics beats Esperion Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Esperion Therapeutics (NASDAQ:ESPR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Esperion Therapeutics'average media sentiment score.

Company	Overall Sentiment
MorphoSys	Neutral
Esperion Therapeutics	Neutral

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has higher revenue and earnings than MorphoSys. Esperion Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to MorphoSys' net margin of -226.79%. Esperion Therapeutics' return on equity of -0.14% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Esperion Therapeutics beats MorphoSys on 11 of the 14 factors compared between the two stocks.

How does Esperion Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Esperion Therapeutics (NASDAQ:ESPR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Esperion Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	4.97	-$66.42M	-$1.09	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Tarsus Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Esperion Therapeutics' return on equity of -0.14% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Esperion Therapeutics	0.12%	-0.14%	0.12%

In the previous week, Tarsus Pharmaceuticals had 27 more articles in the media than Esperion Therapeutics. MarketBeat recorded 27 mentions for Tarsus Pharmaceuticals and 0 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.00 beat Tarsus Pharmaceuticals' score of -0.03 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Neutral
Esperion Therapeutics	Neutral

Tarsus Pharmaceuticals presently has a consensus target price of $90.50, indicating a potential upside of 31.87%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 74.21%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Esperion Therapeutics compare to Supernus Pharmaceuticals?

Esperion Therapeutics (NASDAQ:ESPR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

In the previous week, Supernus Pharmaceuticals had 8 more articles in the media than Esperion Therapeutics. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 0 mentions for Esperion Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 0.70 beat Esperion Therapeutics' score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Esperion Therapeutics	Neutral
Supernus Pharmaceuticals	Positive

47.4% of Esperion Therapeutics shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Esperion Therapeutics has higher earnings, but lower revenue than Supernus Pharmaceuticals. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Supernus Pharmaceuticals	$718.95M	3.77	-$38.55M	-$1.92	N/A

Esperion Therapeutics presently has a consensus price target of $5.54, indicating a potential upside of 74.21%. Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 34.69%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Summary

Supernus Pharmaceuticals beats Esperion Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Esperion Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Esperion Therapeutics (NASDAQ:ESPR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Esperion Therapeutics has a net margin of 0.12% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Esperion Therapeutics	0.12%	-0.14%	0.12%

In the previous week, Regencell Bioscience had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Regencell Bioscience and 0 mentions for Esperion Therapeutics. Regencell Bioscience's average media sentiment score of 1.87 beat Esperion Therapeutics' score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Very Positive
Esperion Therapeutics	Neutral

Regencell Bioscience has higher earnings, but lower revenue than Esperion Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESPR vs. The Competition

Export

Metric	Esperion Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$819.45M	$11.87B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.34%
P/E Ratio	-53.00	783.30	268.76	25.28
Price / Sales	2.03	745.75	583.62	76.23
Price / Cash	N/A	70.00	72.26	50.42
Price / Book	-2.52	10.58	13.15	6.23
Net Income	-$22.68M	$2.78B	$3.45B	$347.51M
7 Day Performance	N/A	0.35%	1.92%	1.38%
1 Month Performance	N/A	-1.58%	-0.33%	-0.55%
1 Year Performance	77.65%	166.20%	70.52%	21.00%

Esperion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESPR Esperion Therapeutics	1.9689 of 5 stars	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200
ARQT Arcutis Biotherapeutics	4.0974 of 5 stars	$25.92 +2.5%	$35.57 +37.2%	+84.8%	$3.18B	$376.07M	123.43	150	Earnings Report Analyst Revision
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TARS Tarsus Pharmaceuticals	2.8868 of 5 stars	$67.76 +4.6%	$90.17 +33.1%	+38.7%	$2.84B	$451.36M	N/A	50	Earnings Report Analyst Forecast Analyst Revision
SUPN Supernus Pharmaceuticals	4.0766 of 5 stars	$47.07 -1.2%	$62.83 +33.5%	+15.6%	$2.77B	$830.44M	N/A	580

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESPR) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Esperion Therapeutics (ESPR) Competitors

ESPR vs. ARQT, MOR, TARS, SUPN, and RGC

How does Esperion Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Esperion Therapeutics compare to MorphoSys?

Summary

How does Esperion Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Esperion Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Esperion Therapeutics compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Esperion Therapeutics (ESPR) Competitors

ESPR vs. ARQT, MOR, TARS, SUPN, and RGC

How does Esperion Therapeutics compare to Arcutis Biotherapeutics?

Do insiders and institutionals believe in ARQT or ESPR?

Does the media favor ARQT or ESPR?

Which has higher earnings & valuation, ARQT or ESPR?

Do analysts recommend ARQT or ESPR?

Which has more risk & volatility, ARQT or ESPR?

Is ARQT or ESPR more profitable?

Summary

How does Esperion Therapeutics compare to MorphoSys?

Does the media favor MOR or ESPR?

Do insiders and institutionals believe in MOR or ESPR?

Which has more volatility & risk, MOR or ESPR?

Do analysts rate MOR or ESPR?

Which has preferable earnings & valuation, MOR or ESPR?

Is MOR or ESPR more profitable?

Summary

How does Esperion Therapeutics compare to Tarsus Pharmaceuticals?

Do institutionals & insiders believe in TARS or ESPR?

Which has better earnings & valuation, TARS or ESPR?

Which has more risk & volatility, TARS or ESPR?

Is TARS or ESPR more profitable?

Does the media refer more to TARS or ESPR?

Do analysts prefer TARS or ESPR?

Summary

How does Esperion Therapeutics compare to Supernus Pharmaceuticals?

Does the media refer more to ESPR or SUPN?

Do institutionals and insiders have more ownership in ESPR or SUPN?

Which has preferable valuation and earnings, ESPR or SUPN?

Do analysts rate ESPR or SUPN?

Which has more volatility and risk, ESPR or SUPN?

Is ESPR or SUPN more profitable?

Summary

How does Esperion Therapeutics compare to Regencell Bioscience?

Is RGC or ESPR more profitable?

Does the media favor RGC or ESPR?

Which has preferable earnings and valuation, RGC or ESPR?

Do institutionals & insiders have more ownership in RGC or ESPR?

Which has more volatility & risk, RGC or ESPR?

Do analysts recommend RGC or ESPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR vs. The Competition

Esperion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools